Thank you, Chair. Thank you, witnesses, for coming this morning.
We're probably going to agree to disagree on a lot of things that have been said here among your groups, but you have raised my curiosity about some things, which I'd like to talk about a little more.
Sandra, you talked about generic drugs and how important it is that we get those on the market as quickly as possible to keep our drug costs down. How important is it to get the new drugs that we need, that are going to keep people out of hospital beds, the facilities? Have you done any work on that?
Then, when a company brings in these new drugs, how do you allow them to have the appropriate period to recover the costs in the research and development of maybe six drugs that don't go to market, and all of a sudden they do get one that does go to market. How do you find that balance?